News Breaks |
|
|
| December 19, 2012 |
| 19:48 EDT |  | PFE, VVUS, AZN, JNJ | VIVUS shares rising on takeover speculation, the Daily Mail reports
There is speculation that Johnson & Johnson (JNJ) and AstraZeneca (AZN) are considering a takeover of VIVUS (VVUS) due to the company's obesity drug Qsymia, according to the Daily Mail, which also speculated that Pfizer (PFE) could look at VIVUS "should it come under corporate attack." Any deal with a chance at success would need to be "in the region of $30-plus a share," the Daily Mail added. Reference Link |
|
|
News For VVUS;JNJ;AZN;PFE From The Last 14 Days Check below for free stories on VVUS;JNJ;AZN;PFE the last two weeks. |
|
|
| June 17, 2013 |
| 12:08 EDT |  | JNJ | J&J deal not negative for Medivation, says Citigroup
 Subscribe for More Information |
|
| 08:36 EDT |  | PFE | InSite Vision to join Merck, Pfizer patent suit against Mylan
InSite Vision (INSV) announced that it will join Merck (MRK) and Pfizer (PFE) in filing a patent infringement lawsuit against Mylan Pharmaceuticals (MYL). Mylan recently filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration seeking to market a generic version of AzaSite before expiration of the patents covering AzaSite and its use. AzaSite is marketed by Merck in the U.S. On May 26, 2011, InSite and Merck filed a similar patent infringement lawsuit against Sandoz. A trial date for the Sandoz ANDA suit has been set for July 11, 2013. The companies have agreed that Merck will take the lead in prosecuting both lawsuits. Each company will be responsible for their own legal costs, with InSite assuming a monitoring role, the company said. |
|
| 08:04 EDT | | JNJ | Johnson & Johnson agrees to acquire Aragon Pharmaceuticals
Johnson & Johnson announced a definitive agreement to acquire Aragon Pharmaceuticals, a privately-held, pharmaceutical discovery and development company focused on drugs to treat hormonally-driven cancers. The acquisition includes Aragon's androgen receptor antagonist program. Aragon's lead product candidate is a second generation androgen receptor signaling inhibitor, ARN-509, in Phase 2 development for castration resistant prostate cancer. Under the terms of the agreement, Johnson & Johnson will make an upfront cash payment of $650M, plus additional contingent payments of up to $350M based on reaching predetermined milestones. The transaction is expected to close in the third quarter of 2013. |
|
| 07:28 EDT |  | AZN, PFE | Cambridge Healthtech Institute to host a conference
Subscribe for More Information |
|
| 07:11 EDT | | VVUS | VIVUS urges stockholders to vote on the GOLD proxy card
VIVUS mailed a letter to stockholders advising them to protect the value of their investment in VIVUS by voting the GOLD proxy card. The letter stated "VIVUS stockholders face an important decision at the upcoming 2013 VIVUS Annual Meeting of Stockholders. Your board and management team have made substantial progress in laying the foundation for Qsymia, and now we are poised to drive future sales by providing broad access to the millions of patients whose lives would benefit from this important therapy. While much progress has already been made, careful and timely execution of the next phase of our retail commercialization plan will be critical to the success of VIVUS. This phase of our retail commercialization plan, after REMS modification, requires a major pharmaceutical company to reach the primary care physicians. As such, we are in discussions with large pharmaceutical companies to explore opportunities as to how we may work together to maximize sales of Qsymia. We strongly believe that electing First Manhattan nominees at the Annual Meeting will jeopardize the progress we are making, and will throw VIVUS into turmoil. At this critical juncture in the company's history, FMC, which owns less than 10% of the company's stock, is trying to seize control of 100% of the VIVUS Board and your company. We strongly urge you not to jeopardize the important progress your Board and management team are making and risk your investment." |
|
| June 16, 2013 |
| 14:45 EDT | | JNJ | J&J's Depuy Synthes unit wins $16M in patent case, Bloomberg says
Subscribe for More Information |
|
| June 14, 2013 |
| 16:00 EDT |  | PFE | Options Update; June 14, 2013
Subscribe for More Information |
|
| 15:49 EDT | | JNJ | J&J's Mentor gets FDA approval for MemoryShape breast implants
Mentor Worldwide announced earlier the U.S. Food and Drug Administration has approved MENTOR MemoryShape breast implants. The open-label, multi-center MENTOR MemoryShape Breast Implant Core Study showed the implants were safe and effective in both reconstruction and augmentation patients at 6 years, with a low rate of adverse events, such as rupture and capsular contracture Baker grades III and IV. Post approval studies will be conducted to collect additional clinical data for the MemoryShape implants. Mentor joined the Johnson & Johnson family of companies in 2009 and is part of its Global Surgery Group. |
|
| 09:03 EDT | | AZN | Bristol-Myers, AstraZeneca to present 33 abstracts at ADA Scientific Sessions
AstraZeneca (AZN) and Bristol-Myers Squibb (BMY) announced that 33 abstracts on the companies’ research in diabetes have been accepted for presentation at the 73rd Scientific Sessions of the American Diabetes Association in Chicago, June 21-25. The data include studies from five marketed products as well as dapagliflozin, an investigational compound in the U.S., currently approved for use in the European Union, Australia, New Zealand and Mexico. Key presentations include: the first presentation of Phase IIa pilot data exploring the use of dapagliflozin in adult patients with type 1 diabetes; four-year data examining the durability of dapagliflozin vs. glipizide as add-on therapies in patients with type 2 diabetes inadequately controlled on metformin; study evaluating the efficacy and tolerability of saxagliptin in patients with type 2 diabetes and a history of cardiovascular disease; three-year data from a study examining the effect of exenatide once weekly on sustained glycemic control and weight compared with insulin glargine; and Phase IV study examining glycemic control, weight, and hypoglycemia with exenatide compared to mealtime administration of rapid-acting analog insulin. |
|
| 06:45 EDT | | PFE | Zoetis volatility elevated into Pfizer split-off
Subscribe for More Information |
| |
| June 13, 2013 |
| 17:39 EDT |  | JNJ | J&J files to sell 25.38M shares of Elan
Subscribe for More Information |
|
| 16:00 EDT | | PFE | Options Update; June 13, 2013
Subscribe for More Information |
|
| 11:02 EDT | | JNJ | Leerink's major pharma analyst holds an analyst/Industry conference call
Subscribe for More Information |
|
| 08:24 EDT | | JNJ | J&J unit says data show Stelara improved components of psoriatic arthritis
Janssen Research & Development, one of the Janssen Pharmaceutical Companies of Johnson & Johnson, announced that results from a Phase 3 study published in The Lancet showed patients with active psoriatic arthritis who received either STELARA 45 mg or 90 mg achieved significant improvement in joint symptoms at the study's primary endpoint compared with patients receiving placebo. According to findings from the investigational study, continued treatment with STELARA every 12 weeks resulted in improvements in signs and symptoms of active disease and psoriasis symptoms through one year. In December 2012, Janssen announced submissions to health authorities in the U.S. and Europe seeking approval of STELARA for the treatment of active psoriatic arthritis. STELARA is approved for the treatment of adults with moderate to severe plaque psoriasis in 72 countries. |
|
| 07:32 EDT | | AZN, PFE | European League Against Rheumatism to host annual meeting
Subscribe for More Information |
|
| June 12, 2013 |
| 17:56 EDT | | JNJ | Johnson & Johnson's Cordis receives FDA clearance for Adroit catheter
Subscribe for More Information |
|
| 16:02 EDT | | PFE | Options Update; June 12, 2013
Subscribe for More Information |
|
| 13:31 EDT | | PFE | Mylan could be interested in generic assets split from Pfizer, Bloomberg says
|
|
| 13:15 EDT | | AZN | Bristol-Myers, AstraZeneca issue statement on review of some therapies
Subscribe for More Information |
|
| 09:13 EDT | | AZN | Amgen, AstraZeneca to advance brodalumab into Phase 3 studies
Subscribe for More Information |
| |
|
|
|
|
